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Abstract
Background: Lactic acid bacteria (LAB) are beneficial probiotic organisms that contribute to
improved nutrition, microbial balance, and immuno-enhancement of the intestinal tract, as well as
lower cholesterol. Although present in many foods, most trials have been in spreads or dairy
products. Here we tested whether Bifidobacteria isolates could lower cholesterol, inhibit harmful
enzyme activities, and control fecal water content.
Methods: In vitro culture experiments were performed to evaluate the ability of Bifidobacterium
spp. isolated from healthy Koreans (20~30 years old) to reduce cholesterol-levels in MRS broth
containing polyoxyethanylcholesterol sebacate. Animal experiments were performed to investigate
the effects on lowering cholesterol, inhibiting harmful enzyme activities, and controlling fecal water
content. For animal studies, 0.2 ml of the selected strain cultures (10
8~10
9 CFU/ml) were orally
administered to SD rats (fed a high-cholesterol diet) every day for 2 weeks.
Results: B. longum SPM1207 reduced serum total cholesterol and LDL levels significantly (p <
0.05), and slightly increased serum HDL. B. longum SPM1207 also increased fecal LAB levels and
fecal water content, and reduced body weight and harmful intestinal enzyme activities.
Conclusion: Daily consumption of B. longum SPM1207 can help in managing mild to moderate
hypercholesterolemia, with potential to improve human health by helping to prevent colon cancer
and constipation.
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Probiotic bacteria have multiple potential health effects,
including blocking gastroenteric pathogens [1-4], neu-
tralizing food mutagens produced in the colon [1,5-10],
enhancing the immune response [6,9,11-14], lowering
serum cholesterol, and stopping intestinal dysfunction
[15-21]. In general, probiotic bacteria must colonize the
gastrointestinal tract (GIT) of the host, have acid- and
bile salt-tolerance, and block putrefactive bacteria in the
GIT. Lactic acid bacteria (LAB), especially Lactobacillus
spp. and Bifidobacterium spp. are important GIT residents
and are used as probiotic strains to improve health
[22-24]. Lactobacillus and Bifidobacterium have been used
in fermented foods for several centuries without adverse
effects [25,26] and are classified as Generally Recognized
as Safe (GRAS) because of their long history of safe use,
particularly in dairy foods [27,28].
Here, we evaluated the ability of Bifidobacteria spp.
isolated from healthy Koreans (20~30 years old) to
lower cholesterol, inhibit harmful enzyme activities, and
control the fecal water content.
Materials and methods
Bacterial strains
The origins of the strains used in this study are shown in
Table 1. Isolation of Bifidobacteria was performed from fecal
samples of healthy Koreans (20~30 years old) collected by
BBL's anaerobic sample collection and transport system to
maintain anaerobic conditions, and were used within 24 h.
Fecalsampleswereseriallydiluted10-foldfrom10
-1to10
-8,
and 100 μl was spread onto selective BL agar containing 5%
sheep blood. After 48 h of incubation in anaerobic
conditions (90% N2,5 %H 2,5 %C O 2) (Bactron Anaerobic
Chamber, Sheldon Manufacturing Inc., USA) at 37°C,
brownorreddish-browncolonies2~3mmindiameterwere
selected for further identification [29].
A fructose-6-phosphate phosphoketolase (F6PPK) test
was performed [30] to ensure that the colonies selected
were Bifidobacteria. To identify the isolated Bifidobacter-
ium spp. at the species level, 16s rRNA sequencing was
performed by Bioleaders (Daejeon, Korea).
In vitro cholesterol-lowering test
MRS broth (pH7.0) (Difco, USA) containing 0.05% L-
cysteine·HCl·H2O (w/v) was prepared and autoclaved
at 121°C for 15 min. Soluble cholesterol (polyoxyetha-
nyl-cholesterol sebacate, Sigma, USA) was added to the
prepared MRS broth and filtered through a 0.45 μm
Millipore filter. The inoculation volume was 15 μlo f
provisional probiotic bacterial culture (10
8~10
9 CFU/
ml) solution per 1 ml cholesterol-MRS broth, and that
was anaerobically incubated at 37°C for 24 h. Unin-
oculated MRS broth was also incubated at 37°C for 24 h
for the control.
Following incubation, bacterial cells were removed by
centrifugation (3,000 rpm, 10 min), and the spent broth
a n du n i n o c u l a t e dc o n t r o lb r o t hw e r et h e na s s a y e df o r
their cholesterol content. The remaining volume of
cholesterol in the cholesterol-MRS broth was determined
by the method reported by Rudel and Morris with a
small modification [31]. To measure the amount of
cholesterol, the dye layer is observed at 560 nm.
Experimental animals and diets
A total of 24 Sprague-Dawley (SD) male rats (5-week-
old) were purchased from Central Lab Animal Inc.
(Korea), and were housed in a temperature-controlled
animal room (22 ± 2°C) with a 12 h light/dark cycle and
humidity 55 ± 5%. Food and water were freely supplied.
The animals were randomly selected and assigned to
three groups (8 rats per group) according to the type of
diet. Group 1 was fed a normal diet. Group 2 was fed a
high-cholesterol diet and saline (as control). Group 3
was fed a high-cholesterol diet and B. longum SPM1207
(the best strain at lowering cholesterol in vitro).
The composition of high-cholesterol feed is shown in
T a b l e2 .A l lt h er a t sw e r ea c c l i m a t i z e dt ot h er e s p e c t i v e
diets for a week before the experiment started. Rats in
groups 2 or 3 received daily administrations of 0.2 ml of
saline or B. longum SPM1207 (10
8~10
9 CFU/ml),
respectively, for 2 weeks. Body weight was monitored
weekly and food consumption was monitored daily.
Analysis of blood serum
At the end of the experimental period of 3 weeks, blood
samples from each animal were collected into tubes by
cardiac puncture to determine the serum cholesterol
level. Serum was separated from the blood by centrifu-
gation at 3,500 rpm for 10 min. The total cholesterol,
HDL-cholesterol, and LDL-cholesterol were analyzed by
Samkwang Lab (Korea).
Table 1: List of lactic acid bacteria used in this study
Bacterial strains Source Origin
Bifidobacterium adolescentis SPM1005 Isolate
a Human feces
Bifidobacterium longum SPM1207 Isolate Human feces
Bifidobacterium adolescentis SPM1601 Isolate Human feces
Bifidobacterium adolescentis KCTC3352 Commercial
b Intestine of adult
Bifidobacterium longum KCTC3128 Commercial Intestine of adult
Lactobacillus acidophilus (LH) CBT Commercial NA
c
Lactobacillus plantarum KCTC1048 Commercial NA
Lactobacillus plantarum (LP) CBT Commercial NA
Enterococcus faecium SPM1206 Isolate Human feces
aIsolated from healthy Korean.
bPurchased from Korean Collection for Type Culture (KCTC).
cNot available.
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Fecal samples were collected weekly to determine the
number of LAB, harmful enzyme activity, and water
content. Fecal samples were taken directly from the
rectum by rectal stimulation and immediately trans-
ferred into sterile tubes and kept at 4°C. Total LAB
counts was performed on MRS-agar and incubated at
37°C for 48 h under anaerobic conditions (90% N2,5 %
H2,5 %C O 2). The numbers of colony forming units
(CFU) are expressed as log10 CFU per gram.
Harmful enzyme activity of rat intestinal microflora
Enzyme activities related to colon cancer were tested in
fecal samples of rats as previously described [32-34].
Tryptophanase activity assay
Tryptophanase activity was assayed using 2.5 ml of a
reaction mixture consisting of 0.2 ml of complete reagent
solution (2.75 mg pyridoxal phosphate, 19.6 mg
disodium EDTA dihydrate, and 10 mg bovine serum
albumin in 100 ml of 0.05 M potassium phosphate
buffer, pH 7.5), 0.2 ml of 20 mM tryptophan, and 0.1 ml
of the enzyme solution (suspended fecal sample),
incubated for 1 h at 37°C, and then stopped by adding
2 ml of color reagent solution (14.7 g p-dimethylami-
nobenzaldehyde in 52 ml H2SO4 and 948 ml 95%
ethanol). The stopped reaction mixture was centrifuged
at 3,000 rpm for 10 min and enzyme activity was
measured by monitoring absorbance at 550 nm.
Urease activity assay
Urease activity was assayed using 0.5 ml of a reaction
mixture consisting of 0.3 ml of urea substrate solution (4
mM urea in 20 mM sodium phosphate buffer, pH 7.0) and
0.1 ml of the enzyme solution (suspended fecal sample)
incubated for 30 min at 37°C and then stopped by adding
0.1 ml of 1 N (NH4)2SO4. Phenolnitroprusside reagent
(1 ml) and alkaline hypochlorite reagent (NaClO, 1 ml)
were added to the stopped reaction mixture and incubated
for 20 min at 65°C. The reaction mixture was centrifuged at
3,000 rpm for 10 min. Enzyme activity was measured by
monitoring absorbance at 630 nm.
b-glucosidase activity assay
b-glucosidase activity was assayed using 2 ml of a
reaction mixture consisting of 0.8 ml of 2 mM p-
nitrophenyl-b-D-glucopyranoside and 0.2 ml of the
enzyme solution (suspended fecal sample), incubated
for 30 min at 37°C, and then stopped by adding 1 ml of
0.5 N NaOH. The stopped reaction mixture was
centrifuged at 3,000 rpm for 10 min. Enzyme activity
was measured by monitoring absorbance at 405 nm.
b-glucuronidase activity assay
b-glucuronidase activity was assayed using 2 ml of a
reaction mixture consisting of 0.8 ml of 2 mM p-
nitrophenyl-b-D-glucuronide and 0.2 ml of the enzyme
solution (suspended fecal sample), incubated for 30 min
at 37°C, and then stopped by adding 1 ml of 0.5 N
NaOH. The stopped reaction mixture was centrifuged at
3,000 rpm for 10 min. Enzyme activity was measured by
monitoring absorbance at 405 nm.
Measurement of fecal water content
The water content of fecal samples was measured using a
drying oven (105°C, 24 h). Fecal water content (%) is
calculated by:
Fecal water content
Wwet Wdry
Wwet
(%) =
−
×100
where Wwet and Wdry a r et h ew e i g h to ft h ef e c a ls a m p l e
before and after drying in the oven.
Statistical Analysis
Results were expressed as mean ± standard deviation
(SD). For statistical evaluation of data, one-way ANOVA
was applied using SPSS 13.0 for Windows followed by
post hoc comparisons using the Tukey's test. Differences
were considered significant at p <0 . 0 5 .
Results
Isolation and characterization of B. longum SPM1207
B. longum SPM1207 isolated from healthy Korean faeces
was Gram-positive rods, with a translucent glossy colony
on general anaerobic medium (GAM, Nissui Pharm. Co.
Ltd., Japan) under anaerobic conditions (90% N2,5 %
H2,5 %C O 2). Sequence analysis (Figure 1) and BLAST
Table 2: Compositions of high-cholesterol diets for SD rats
Ingredients Compositions
g kcal
Casein (from milk) 200 800
Corn Starch 155.036 620
Sucrose 50 200
Dextrose 132 528
Cellulose 50 0
Soybean Oil 25 225
Lard 175 1575
Mineral Mixture 35 0
Vitamin Mixture 10 40
TBHQ 0.014 0
DL-Methionine 0 0
L-Cystine 3 12
Choline Bitartrate 2.5 0
Total 838 4,000
Cholesterol 20 g/kg (2%)
Cholic acid 5 g/kg (0.5%)
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strain showed 99% homology with Bifidobacterium
longum DJO10A.
In vitro cholesterol-lowering test
Amongthetestedstrains,B.longumSPM1207hadthehighest
cholesterol-reducing activities in MRS broth containing
cholesterol (Table 3). On average, Bifidobacterium showed
higher cholesterol-reducing activities than Lactobacillus.A n d
the strains presented different cholesterol lowering effects
despite being the same species. The effect of B. longum
S P M 1 2 0 7w a s2t i m e sh i g h e rt h a nB. longum KCTC3128.
Lowering of serum cholesterol in rats
We then tested the hypocholesterolemic effects of this LAB
in rats fed a high-cholesterol diet. A high cholesterol diet
increased serum cholesterol levels (Table 4). B. longum
SPM1207 treatment reduced total cholesterol from 111.3
to 84.4 mg/dl and LDL-cholesterol levels from 33.3 to
23.5mg/dl.Inaddition,B.longumSPM1207slightlyincreased
HDL-cholesterol levels, but did not significantly (Table 4).
Fecal water content, body weight, and bacteriological
analysis
The high cholesterol diet caused dry feces, but B. longum
SPM1207 treatment increased fecal water content(Figure 2).
The high cholesterol diet also increased body weight after
2 weeks, but B. longum SPM1207 blocked this increase
(Figure3). Fecal LAB counts weresimilar in allgroups before
the experimental diets, but a high-cholesterol diet lowered
LAB counts. LAB administration increased fecal LAB counts
from 5.3 log10 CFU/g to 6.9 log10 CFU/g, which was
significantly higher than controls (Figure 4).
Inhibitory effect on harmful enzyme of rat intestinal
microflora
B. longum SPM1207 significantly inhibited tryptopha-
nase and urease activities and slightly decreased b-
glucosidase and b-glucuronidase activities (Figure 5).
Discussion
Cardiovascular disease is the most important cause of
death in westernized countries, including Korea. In the
United States, 10 million people suffer from ischemic
coronary arterial diseases, and spend 115 billion dollars
per year to treat it [19]. According to NHANES (the third
national health and nation examination survey) data
and NCEP (national cholesterol education program)
guide, a half million people have died of ischemic
cardiac disease. [19,35].
Hypercholesterolemia is strongly associated with coron-
ary heart disease and arteriosclerosis [35-38], and
decreasing serum cholesterol is an important treatment
option. HDL-cholesterol can prevent arteriosclerosis by
removing cholesterol from the blood stream, whereas
LDL-cholesterol causes accumulation of cholesterol in
blood vessels [35,39]. According to Frick et al. [40], every
1% reduction in body cholesterol content lowers the risk
for cardiovascular diseases by 2%. Therapeutic lifestyle
changes including dietary interventions, in particular a
reduction of saturated fat and cholesterol, are established
as a first line therapy to reduce LDL-cholesterol. A change
in dietary habits, such as eating fermented products
GNNNNGNNTTTCCGGNATTATTGGGCGTAAGGGCTCGTAGGCGGTTCGTCGCGTCCGGTGTGAAAGTCCATCGCTTAACGGTG
GATCCGCGCCGGGTACGGGCGGGCTTGAGTGCGGTAGGGGAGACTGGAATTCCCGGTGTAACGGTGGAATGTGTAGATATCGG
GAAGAACACCAATGGCGAAGGCAGGTCTCTGGGCCGTTACTGACGCTGAGGAGCGAAAGCGTGGGGAGCGAACAGGATTAG
ATACCCTGGTAGTCCACGCCGTAAACGGTGGATGCTGGATGTGGGGCCCGTTCCACGGGTTCCGTGTCGGAGCTAACGCGTTA
AGCATCCCGCCTGGGGAGTACGGCCGCAAGGCTAAAACTCAAAGAAATTGACGGGGGCCCGCACAAGCGGCGGAGCATGCG
GATTAATTCGATGCAACGCGAAGAACCTTACCTGGGCTTGACATGTTCCCGACGGTCGTAGAGATACGGCTTCCCTTCGGGGCG
GGTTCACAGGTGGTGCATGGTCGTCGTCAGCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAACGAGCGCAACCCTCGCCCC
GTGTTGCCAGCGGATTATGCCGGGAACTCACGGGGGACCGCCGGGGTTAACTCGGAGGAAGGTGGGGATGACGTCAGATCA TC
ATGCCCCTTACGTCCAGGGCTTCACGCATGCTACAATGGCCGGTACAACGGGATGCGACGCGGCGACGCGGAGCGGATCTCTG
AAAACCGGTCTCAGTTCGGATCGCAGTCTGCAACTCGACTGCGTGAAGGCGGAGTCGCTAGTAATCGCGAATCAGCAACGTCG
CGGTGAATGCGTTCCCGGGCCTTGTACACACCGCCCGTCAAGTCATGAAAGTGGGCAGCAC
Figure 1
Sequence analyses of the B. longum SPM1207-16s
rRNA gene shows 99% identity with B. longum
DJO10A (879 bp).
Table 3: Amount of residual cholesterol after in vitro incubation of selected lactic acid bacteria
Species Residual cholesterol
(mg/dl)
Cholesterol lowering ratio (%) p value
Control
a 345.0 ± 5.7
b --
Bifidobacterium adolescentis SPM1005 318.7 ± 3.0 7.6 p <0 . 0 5
c
Bifidobacterium longum SPM1207 262.8 ± 1.3 23.8 p <0 . 0 5
Bifidobacterium adolescentis SPM1601 283.3 ± 2.6 17.9 p <0 . 0 5
Bifidobacterium adolescentis KCTC3352 329.0 ± 5.6 4.6 p <0 . 0 5
Bifidobacterium longum KCTC3128 303.8 ± 6.0 11.9 p <0 . 0 5
Lactobacillus acidophilus (LH) CBT 321.7 ± 1.9 6.7 p <0 . 0 5
Lactobacillus plantarum KCTC1048 314.0 ± 4.4 9.0 p <0 . 0 5
Lactobacillus plantarum (LP) CBT 296.3 ± 5.0 14.1 p <0 . 0 5
Enterococcus faecium SPM1206 300.9 ± 1.7 12.8 p <0 . 0 5
aMRS broth containing cholesterol without lactic acid bacteria.
bEach value provided is the mean ± SD.
cp < 0.05 significantly different compared with control.
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Since the early studies of Mann and Spoerry [41], the
cholesterol-lowering potential of lactic acid bacteria such
as Lactobacillus and Bifidobacterium is commonly studied
in vitro or in vivo (experimental animals and human
subjects) [21,23,36,42-46].
Here, B. longum SPM1207 isolated from healthy Korean
feces had hypocholesterolemic effects in vitro and in
experimental animals (from 345.0 mg/dl to 262.8 mg/
dl, and 111.3 mg/dl to 84.8 mg/dl, respectively). B.
longum SPM1207 also slightly increased HDL-cholesterol
levels, in agreement with other findings that decreased
total cholesterol was accompanied by simultaneous
increases of HDL-cholesterol [47,48].
Cholesterol reduction by lactic acid bacteria can be
explained by five mechanisms [49-54]: (a) fermentation
products of lactic acid bacteria inhibit cholesterol
synthesis enzymes and thus reduce cholesterol produc-
tion; (b) the bacteria facilitate the elimination of
cholesterol in feces; (c) the bacteria inhibit the absorp-
tion of cholesterol back into the body by binding with
Table 4: Effects of the B. longum SPM1207 on serum total-, HDL-,
and LDL-cholesterol of SD rats fed on a high-cholesterol diet
Index Basal diet High-cholesterol diet p value
Control SPM1207
b
Total cholesterol
(mg/dl)
55.0 ± 5.5
a 111.3 ± 25.2 84.8 ± 4.3 p <0 . 0 5
c
HDL
e-cholesterol
(mg/dl)
23.9 ± 1.4 30.0 ± 2.6 30.6 ± 1.5 NS
d
LDL
f-cholesterol
(mg/dl)
11.6 ± 1.1 33.3 ± 8.5 23.5 ± 2.3 p <0 . 0 5
aEach value provided is the mean ± SD for 8 rats.
bBifidobacterium longum SPM1207 isolated from healthy Korean.
cp < 0.05 significantly different compared with control.
dNS: not significant.
eHDL: high density lipoprotein.
fLDL: low density lipoprotein.
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of bile salt (a metabolic product of cholesterol) and
facilitate its elimination, which raises the demand for
bile salt made from cholesterol and thus results in body
cholesterol consumption; and, (e) due to the assimila-
tion of lactic acid.
Lactic acid bacteria have anti-tumor effects [6,8,9,55,56]
and block harmful intestinal enzyme activities, a
recognized risk factor for colon cancer [8,57,58]. Con-
sumption of L. rhamnosus GG decreased the activity of
b-glucuronidase [59,60], nitroreductase [60], and cho-
lylglycine hydrolase [60,61]. Consumption of milk
enriched with L. casei for 4 weeks temporarily decreased
b-glucuronidase activity in 10 healthy men but not in 10
healthy control subjects [62]. Consumption of milk
fermented with a Bifidobacterium species decreased b-
glucuronidase activity compared with baseline but did
not affect fecal pH or the activity of nitrate reductase,
nitroreductase, and azoreductase [63]. Consumption of
fermented milk with L. acidophilus, B. bifidum, Strepto-
coccus lactis,a n dStreptococcus cremoris for 3 weeks
decreased nitroreductase activity but not b-glucuronidase
and azoreductase [64].
Here, B. longum SPM1207 decreased tryptophanase, urease,
b-glucosidase,andb-glucuronidaseinrats.FecalLABcounts
intheB.longumSPM1207feedinggroupwasabout10times
greater than that in the control group, indicating bacterial
survival through the gastrointestinal tract.
Conclusion
In conclusion, the incorporation of B. longum SPM1207
in the diet suppressed serum cholesterol levels on a
cholesterol-enriched diet. This LAB also improved the
balance of the intestinal flora, improved tryptophanase,
urease, b-glucosidase, and b-glucuronidase, and
increased fecal LAB levels and fecal water content.
Therefore, B. longum SPM1207 may be a functional
probiotic to treat hypercholesterolemia, help prevent
colon cancer, and constipation. Studies in humans,
however, could be resulted in contradictory outcomes.
So, further clinical trials to confirm these effects must be
conducted.
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